Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is caused by a metabolic-induced inflammation of the liver and is one of the major causes of liver fibrosis and cirrhosis. Its symptoms are often silent or non-specific to MASH, making it difficult to diagnose. It is an area of high unmet medical need with no approved treatments currently available. MASH is the more serious form of metabolic dysfunction associated steatotic liver disease (MASLD), which is the most common liver disease in Western industrialized nations, affecting one out of four adults. MASH and MASLD are especially prevalent in, but not limited to, people with metabolic disorders such as type 2 diabetes and obesity. The prevalence of MASH is estimated to effect over 250 million people worldwide.
